Search

Displaying results 5441 - 5450 of 8974 in total
  1. Drug

    Iron isomaltoside 1000

    go.drugbank.com/drugs/DB12208
    ApprovedInvestigationalWithdrawn

    Iron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.

  2. Drug

    Ranpirnase

    go.drugbank.com/drugs/DB04950
    Investigational

    It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.

  3. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). … When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time.

  4. Drug

    Vasomera

    go.drugbank.com/drugs/DB16498
    Investigational

    Categories: Experimental Unapproved Treatments for COVID-19
  5. Drug

    Mosedipimod

    go.drugbank.com/drugs/DB12592
    Investigational

    Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    Loteprednol

    go.drugbank.com/drugs/DB00873
    ApprovedInvestigationalWithdrawn

    Loteprednol is a corticosteroid. A more commonly used formulation of loteprednol is its ester, loteprednol etabonate.

  7. Drug

    KF-0210

    go.drugbank.com/drugs/DB17476
    Investigational

    KF-0210 is a small molecule developed by Keythera Pharmaceuticals. It is being investigated for cancers.

  8. Drug

    Cardarine

    go.drugbank.com/drugs/DB05416
    Investigational

    Cardarine has been investigated for the treatment of Obesity, Lipid Disorders, and Cardiovascular Disease. … Cardarine (GW-501516) is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia.

  9. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016. … [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.

  10. Drug

    Upanovimab

    go.drugbank.com/drugs/DB16505
    Investigational

    Upanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19

    Categories: Experimental Unapproved Treatments for COVID-19